The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The results showed a 30% spleen response rate and a 47% symptom response rate among evaluable patients. Overall survival reached around 37 months, which compares favorably to historical controls where survival is typically between one and three years.
William Wierda, MD, PhD, is a professor of medicine and center medical director for the Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
In this multiple myeloma roundtable from EHA 2026, the roundtable panelists evaluate the strategic sequencing of mezigdomide-based therapy, its potential as a bridging strategy, and its practical logistical advantages in community-based practices compared to T-cell redirecting therapies.
The United States Food and Drug Administration has approved a rituximab biosimilar candidate developed by pharmaceutical company Dr. Reddy’s Laboratories.
Dr. Ponce outlines bone health parameters for axatilimab, a high-affinity anti-CSF-1R monoclonal antibody.
ASCO’s first guideline on ctDNA testing in solid tumors and lymphoma was published by Christina Lockwood, PhD, head of the Genetics and Solid Tumors Laboratory at the University of Washington Medical Center, in the Journal of Clinical Oncology in June.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
![Insider_YT_Feature_Pannunzio_CLFR2_400x400[15]](https://sohoinsider.com/wp-content/uploads/2026/06/Insider_YT_Feature_Pannunzio_CLFR2_400x40015.png)
